New clinical application prospects of artemisinin and its derivatives: a scoping review.

BACKGROUND: Recent research has suggested that artemisinin and its derivatives may have therapeutic effects on parasites, viruses, tumors, inflammation and skin diseases. This study aimed to review clinical research on artemisinin and its derivatives except anti-malaria and explore possible priority areas for future development. METHODS: Relevant articles in English and Chinese published before 28 October 2021 were reviewed. All articles were retrieved and obtained from databases including WanFang, PubMed/MEDLINE, the Cochrane Library, China National Knowledge International, Embase, OpenGrey, the Grey Literature Report, Grey Horizon, and ClinicalTrials.gov. Studies were selected for final inclusion based on predefined criteria. Information was then extracted and analyzed by region, disease, outcome, and time to identify relevant knowledge gaps. RESULTS: Seventy-seven studies on anti-parasitic (35), anti-tumor (16), anti-inflammatory (12), anti-viral (8), and dermatological treatments (7) focused on the safety and efficacy of artemisinin and its derivatives. The anti-parasitic clinical research developed rapidly, with a large number of trials, rapid clinical progress, and multiple research topics. In contrast, anti-viral research was limited and mainly stayed in phase I clinical trials (37.50%). Most of the studies were conducted in Asia (60%), followed by Africa (27%), Europe (8%), and the Americas (5%). Anti-parasite and anti-inflammatory research were mainly distributed in less developed continents such as Asia and Africa, while cutting-edge research such as anti-tumor has attracted more attention in Europe and the United States. At the safety level, 58 articles mentioned the adverse reactions of artemisinin and its derivatives, with only one study showing a Grade 3 adverse event, while the other studies did not show any related adverse reactions or required discontinuation. Most studies have discovered therapeutic effects of artemisinin or its derivatives on anti-parasitic (27), anti-tumor (9), anti-inflammatory (9) and dermatological treatment (6). However, the efficacy of artemisinin-based combination therapies (ACTs) for parasitic diseases (non-malaria) is still controversial. CONCLUSIONS: Recent clinical studies suggest that artemisinin and its derivatives may be safe and effective candidates for anti-tumor, anti-parasitic, anti-inflammatory and dermatological drugs. More phase II/III clinical trials of artemisinin and its derivatives on antiviral effects are needed.

Quality marker discovery of Danggui Jianzhong decoction for treating primary dysmenorrhoea based on chinmedomics strategy.

BACKGROUND: Danggui Jianzhong Decoction (DGJZD) has been proven as an effective classical prescription for clinically treating primary dysmenorrhoea (PD). However, the industrialisation development and drug innovation of DGJZD remain limited due to its undefined effective constituents and quality markers (Q-markers). PURPOSE: Elucidating the Q-markers of DGJZD, which is related to clinical efficacy. METHODS: In accordance with chinmedomics strategy, we evaluated the therapeutic efficacy of DGJZD on the basis of the metabolomic profile and biomarker of a PD rat model to further identify the constituents of DGJZD in vivo that originated from the formula under the acting condition of DGJZD. The potential effective constituents and Q-markers were identified by mining the dynamic relation between the constituents in vivo and the biomarkers. RESULTS: Subsequently, 29 serum metabolites were characterized as biomarkers for PD, and DGJZD adjusted the levels of the primary biomarkers involved in arachidonic acid metabolism, glycerophospholipid metabolism, tryptophan metabolism as well as the synthesis of steroid hormones. Under the active condition of DGJZD, 20 prototype ingredients and 4 metabolites of DGJZD were found in vivo, five of which were mostly related with the efficacy of PD, namely, ferulic acid, zizyphusin, cinnamic acid, protocatechuic acid-3-glucoside, and azelaic acid. They were the potential pharmacodynamic constituents for treating PD, and they could be regarded as the Q-markers of DGJZD. CONCLUSION: Taken together, the Q-markers of DGJZD identified in this research are credible and assist in solving problems related to quality control and drug innovation, accelerating industrialisation development. Besides, the efficacy, mechanism and active ingredients of DGJZD for the treatment of PD were innovatively elucidated for the first time on the basis of the chinmedomics strategy for uncovering the Q-markers of drugs from the system perspective.

Determination of antimicrobial and phytochemical compounds of Jatropha curcas plant.

The aim of this study was to explore the effectiveness of different parts of J. curcas plant against some selected human pathogens as antimicrobial agent which are known to cause diseases and to check antioxidant and phytochemicals from different plant sections of J. curcas. Plant extracts were analyzed by quantification of antimicrobial and phytochemical compounds. This study reveals that 20% ethanol stem extract of J. curcas showed maximum antibacterial activity (40 ± 0.0 mm) against Klebsiella pneumonia. Water extract of root of J. curcas also inhibited E. coli (35.25 ± 0.35 mm). The growth of K. pneumonia and Agrobacterium tumifaciens were also ceased when ethanol extract of J. curcas root applied to check their potential as antimicrobial agent. The results also revealed that fungal species, Aspergillus niger, and Pencillium notatum noted the maximum antifungal activity in ethanol extract of flower and methanol extract of root (38.5 ± 0.7 mm) and (27.25 ± 0.35 mm) respectively. Phytochemicals and many secondary metabolites were present in J. curcas extracts such as alkaloids, steroids, tannins, glycosides, flavonoids, saponins, courmerin, and phenolic compounds. It also showed the highest density of color in the different parts of plant extract of J. curcas. Similarly, biochemical primary metabolites were observed at maximum amount of biochemical in different parts of J. curcas, and correlated with antimicrobial activity. The study concluded that J. curcas has great potential as antibacterial agent and cure various human pathogens.

[Study progress on Pinelliae Rhizoma processed by replication method].

In the clinical practice of traditional Chinese medicine, Pinelliae Rhizoma is a commonly used traditional Chinese medicinal material, with a very important medicinal value, but its raw products have certain toxicity. According to the basic theory of traditional Chinese medicine, after Pinelliae Rhizoma is processed, its toxic and side effects can be reduced, there by ensuring its medication safety in clinic. Based on the processing characteristics of Pinelliae Rhizoma replication method, this article discusses the changes before and after processing of Pinelliae Rhizoma with multiple materials and multiple processes. This method does not have a unified process. One or more materials are added, and various processes, such as dipping, soaking, bleaching, or steaming, cooking or combined methods are adopted. Then, Pinelliae Rhizoma is repeatedly processed to meet the specified quality requirements. By different processing methods, the efficacy changes accordingly, and Pinelliae Rhizoma can be used for the treatment of different diseases. The article starts in the two directions of multi-materials and multi-processes, and summarizes the effects of multi-materials or multi-processes on the chemical composition and efficacy, as well as the processing mechanism of reducing toxicity and increasing efficiency, in the expectation of reducing the toxicity and enhancing the efficacy of Pinelliae Rhizoma. The medicinal scope provides a reference and theoretical basis for further studies on the processing mechanism. An in-depth study is conducted to make Pinelliae Rhizoma more safe and effective in clinic application, and ensure its clinical efficacy. It will provide reference for future studies on quality control, active ingredients and new drug development of the processing of pinellia slices. It has laid a scientific foundation for exploring the best processing techno-logy, and provided a theoretical basis for solving the production problems of processed Pinelliae Rhizoma products, so as to improve the production efficiency and the quality of medicines.

Study progress on Pinelliae Rhizoma processed by replication method / 中国中药杂志

In the clinical practice of traditional Chinese medicine, Pinelliae Rhizoma is a commonly used traditional Chinese medicinal material, with a very important medicinal value, but its raw products have certain toxicity. According to the basic theory of traditional Chinese medicine, after Pinelliae Rhizoma is processed, its toxic and side effects can be reduced, there by ensuring its medication safety in clinic. Based on the processing characteristics of Pinelliae Rhizoma replication method, this article discusses the changes before and after processing of Pinelliae Rhizoma with multiple materials and multiple processes. This method does not have a unified process. One or more materials are added, and various processes, such as dipping, soaking, bleaching, or steaming, cooking or combined methods are adopted. Then, Pinelliae Rhizoma is repeatedly processed to meet the specified quality requirements. By different processing methods, the efficacy changes accordingly, and Pinelliae Rhizoma can be used for the treatment of different diseases. The article starts in the two directions of multi-materials and multi-processes, and summarizes the effects of multi-materials or multi-processes on the chemical composition and efficacy, as well as the processing mechanism of reducing toxicity and increasing efficiency, in the expectation of reducing the toxicity and enhancing the efficacy of Pinelliae Rhizoma. The medicinal scope provides a reference and theoretical basis for further studies on the processing mechanism. An in-depth study is conducted to make Pinelliae Rhizoma more safe and effective in clinic application, and ensure its clinical efficacy. It will provide reference for future studies on quality control, active ingredients and new drug development of the processing of pinellia slices. It has laid a scientific foundation for exploring the best processing techno-logy, and provided a theoretical basis for solving the production problems of processed Pinelliae Rhizoma products, so as to improve the production efficiency and the quality of medicines.

Potential medicinal benefits of Cosmos caudatus (Ulam Raja): A scoping review.

Cosmos caudatus is widely used as a traditional medicine in Southeast Asia. C. caudatus has been reported as a rich source of bioactive compounds such as ascorbic acid, quercetin, and chlorogenic acid. Studies have shown that C. caudatus exhibits high anti-oxidant capacity and various medicinal properties, including anti-diabetic activity, anti-hypertensive properties, anti-inflammatory responses, bone-protective effect, and anti-microbial activity. This review aims to present the potential medicinal benefits of C. caudatus from the available scientific literature. We searched PubMed and ScienceDirect database for articles published from 1995 to January 2015. Overall, 15 articles related to C. caudatus and its medicinal benefits are reviewed. All these studies demonstrated that C. caudatus is effective, having demonstrated its anti-diabetic, anti-hypertensive, anti-inflammatory, bone-protective, anti-microbial, and anti-fungal activity in both in vitro and animal studies. None of the studies showed any negative effect of C. caudatus related to medicinal use. Currently available evidence suggests that C. caudatus has beneficial effects such as reducing blood glucose, reducing blood pressure, promoting healthy bone formation, and demonstrating anti-inflammatory and anti-microbial properties. However, human clinical trial is warranted.

A Herbological Study on the Medicinal Effects and Employments of Rhubarb Processed with Liquor / 日本東洋医学雑誌

From ancient times, the crude drug rhubarb (Da-huang in Chinese, Daio in Japanese) has been processed using liquor in various ways in China. There are mainly three ways of processing it ; liquor-soaking, liquor-dipping and liquor-frying. Today, the liquor-fried rhubarb, appropriately named ‘liquor rhubarb’, is widely used. But it is not clear why use of the rhubarb processed with liquor began. Thus, we researched ancient literature published after the Jin and Yuan dynasties, when medical treatment was done based on the theories. We found that the ‘liquor-soaked rhubarb’ was used as a depurative, while the ‘liquor-dipped rhubarb’ was used as a purgative or a digestive. ‘Liquor-fried rhubarb’ use began after the Ming dynasty, and its medicinal effect was expected to be the same as the two processed rhubarbs of earlier periods.

Studies of Rhei Rhizoma (Da-huang; Daio). (I). A Herbological Study on its Medicinal Effects and Medicinal Parts / 日本東洋医学雑誌

Although the crude drug Rhei Rhizoma (Chinese: Da-huang; Japanese: Daio) is now commonly employed as a purgative, some question remains as to whether it was originally used as a depurative (purifying agent; specifically an agent for expelling Stagnated Blood) or purgative in ancient times. There is also some confusion as to the medicinal part of the crude drug being sold on the market. This herbological study was carried out in order to clarify these issues.<br>The results showed that Rhei Rhizoma was originally used mainly as an agent to expel Stagnated Blood, although it was also used for its purgative and other properties. Until the Qing dynasty, the rhizome of the large Rheum species, including R. palmatum, was known as the best quality Da-huang. The recent use of the root is thought to be due to recognition of the purgative properties of Da-huang.<br>Da-huang has many medicinal properties in addition to its usefulness as a purgative, and there is a need for further study of these properties as well as the differences between the pharmacological actions of the rhizome and those of the root.